Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Biomarker and diagnostic research for monocytic leukemia has been reported in the published literature.
1 FDA-approved treatment is available for monocytic leukemia, including CYCLOPHOSPHAMIDE (CYCLOPHOSPHAMIDE, approved 2021).
Brand Name | Generic Name | Mechanism | Approved | Market Status |
|---|---|---|---|---|
13 clinical trials registered, 5 recruiting. Interventions under study include drug therapy, other interventions, procedural interventions, and biologic therapy. Pipeline includes 6 PHASE2, 3 PHASE1, 1 EARLY_PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT05566054](https://clinicaltrials.gov/study/NCT05566054) |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 8:49 AM UTC
CYCLOPHOSPHAMIDE |
— |
2021 |
Available |
Gene therapy approaches for monocytic leukemia have been reported in the published literature.
13 trials found
Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia |
PHASE2 |
The First Affiliated Hospital of Soochow University |
RECRUITING |
[NCT03670966](https://clinicaltrials.gov/study/NCT03670966) | 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome | PHASE1 | Fred Hutchinson Cancer Center | RECRUITING |
[NCT06950034](https://clinicaltrials.gov/study/NCT06950034) | A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML) | PHASE1 | Solu Therapeutics, Inc | RECRUITING |
[NCT07512700](https://clinicaltrials.gov/study/NCT07512700) | Venetoclax Combined With CACAG Regimen Versus "3+7" Regimen in the Treatment of Acute Monocytic Leukemia | PHASE2 | Chinese PLA General Hospital | RECRUITING |
[NCT03964506](https://clinicaltrials.gov/study/NCT03964506) | Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant | EARLY_PHASE1 | Omar Aljitawi | RECRUITING |
141 publications have been identified in PubMed for monocytic leukemia. Research spans Basic Science / Preclinical (66%), Case Report / Case Series (16%), and Gene Therapy / Novel Therapeutics (8%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 93 | 66% |
Patient case studies | 23 | 16% |
New treatment approaches | 11 | 8% |
Testing and diagnosis research | 4 | 3% |
Research summaries | 4 | 3% |
Other research | 3 | 2% |
Disease patterns and progression | 3 | 2% |
Chen W (2026). [PMID: 41691624](https://pubmed.ncbi.nlm.nih.gov/41691624/). *Cell Rep*. [Basic Science / Preclinical]
Kim S (2026). [PMID: 42021861](https://pubmed.ncbi.nlm.nih.gov/42021861/). *Toxicol Res*. [Basic Science / Preclinical]
Kim KL (2026). [PMID: 42059171](https://pubmed.ncbi.nlm.nih.gov/42059171/). *Malays J Pathol*. [Basic Science / Preclinical]
Li L (2026). [PMID: 41960576](https://pubmed.ncbi.nlm.nih.gov/41960576/). *J Pharm Anal*. [Basic Science / Preclinical]
Jin Y (2026). [PMID: 41624379](https://pubmed.ncbi.nlm.nih.gov/41624379/). *Mediators Inflamm*. [Basic Science / Preclinical]
Ye Y (2026). [PMID: 42225948](https://pubmed.ncbi.nlm.nih.gov/42225948/). *Commun Biol*. [Basic Science / Preclinical]
Shah B (2026). [PMID: 41262051](https://pubmed.ncbi.nlm.nih.gov/41262051/). *Haematologica*. [Basic Science / Preclinical]
Li C (2026). [PMID: 42166383](https://pubmed.ncbi.nlm.nih.gov/42166383/). *J Innate Immun*. [Basic Science / Preclinical]
Freitas TR (2026). [PMID: 40491377](https://pubmed.ncbi.nlm.nih.gov/40491377/). *Anticancer Agents Med Chem*. [Gene Therapy / Novel Therapeutics]
Yu L (2026). [PMID: 41753590](https://pubmed.ncbi.nlm.nih.gov/41753590/). *Microorganisms*. [Basic Science / Preclinical]